Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 17/20 | 0.65 |
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | CTSS | P25774 | 2/20 | 0.57 |
| ▸ | CTSK | P43235 | 2/20 | 0.57 |
| ▸ | CTSH | P09668 | 1/20 | 0.57 |
| ▸ | MC4R | P32245 | 1/20 | 0.57 |
| ▸ | MC5R | P33032 | 1/20 | 0.57 |
| ▸ | MC3R | P41968 | 1/20 | 0.57 |
| ▸ | MC1R | Q01726 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21146569 | 0.97 | IL23R (0.66) | IL23RMC4R | |
| SCHEMBL30464981 | 0.96 | IL23R (0.60) | IL23RCTSLCTSSCTSKCTSH | |
| SCHEMBL30465002 | 0.96 | IL23R (0.60) | IL23RCTSLCTSSCTSKCTSH | |
| SCHEMBL30464993 | 0.94 | IL23R (0.58) | IL23RCTSLCTSSCTSKCTSH | |
| SCHEMBL30464997 | 0.93 | IL23R (0.57) | IL23RCTSLCTSSCTSKCTSH | |
| SCHEMBL18891483 | 0.93 | MC4R (0.62) | IL23RCTSLCTSSCTSKCTSH | |
| SCHEMBL18891548 | 0.93 | MC4R (0.62) | IL23RCTSLCTSSCTSKCTSH | |
| SCHEMBL29814670 | 0.93 | IL23R (0.61) | IL23RMC4R | |
| SCHEMBL30464995 | 0.93 | IL23R (0.61) | IL23RMC4R | |
| SCHEMBL28714609 | 0.92 | IL23R (0.56) | IL23RCTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | IL23R 1115/4885CTSL 800/4885CTSS 1213/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | IL23R 1115/4885CTSL 800/4885CTSS 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.